AU2016363683B2 - Monocarboxylate transporter 4 (MCT4) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer - Google Patents

Monocarboxylate transporter 4 (MCT4) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer Download PDF

Info

Publication number
AU2016363683B2
AU2016363683B2 AU2016363683A AU2016363683A AU2016363683B2 AU 2016363683 B2 AU2016363683 B2 AU 2016363683B2 AU 2016363683 A AU2016363683 A AU 2016363683A AU 2016363683 A AU2016363683 A AU 2016363683A AU 2016363683 B2 AU2016363683 B2 AU 2016363683B2
Authority
AU
Australia
Prior art keywords
seq
cancer
aso
mct4
antisense oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016363683A
Other languages
English (en)
Other versions
AU2016363683A1 (en
Inventor
Stephen Yiu Chuen CHOI
Yuzhuo WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of AU2016363683A1 publication Critical patent/AU2016363683A1/en
Application granted granted Critical
Publication of AU2016363683B2 publication Critical patent/AU2016363683B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2016363683A 2015-11-30 2016-11-30 Monocarboxylate transporter 4 (MCT4) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer Active AU2016363683B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562260837P 2015-11-30 2015-11-30
US62/260,837 2015-11-30
PCT/CA2016/000296 WO2017091885A1 (en) 2015-11-30 2016-11-30 Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2016363683A1 AU2016363683A1 (en) 2018-07-12
AU2016363683B2 true AU2016363683B2 (en) 2023-04-27

Family

ID=58795956

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016363683A Active AU2016363683B2 (en) 2015-11-30 2016-11-30 Monocarboxylate transporter 4 (MCT4) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer

Country Status (9)

Country Link
US (2) US10889814B2 (enExample)
EP (1) EP3384028B1 (enExample)
JP (1) JP7039470B2 (enExample)
CN (1) CN108603194A (enExample)
AU (1) AU2016363683B2 (enExample)
CA (1) CA3006827A1 (enExample)
ES (1) ES2893294T3 (enExample)
MX (1) MX2018006527A (enExample)
WO (1) WO2017091885A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017091885A1 (en) 2015-11-30 2017-06-08 The University Of British Columbia Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer
MX2019001389A (es) 2019-01-31 2020-02-20 Atso Corp Affairs S A De C V Oligonucleotidos antisentido de las glutation s transferasa para el tratamiento del cancer.
EP3999117A4 (en) * 2019-07-12 2023-07-26 Duke University NANOPARTICLE SYSTEMS FOR TARGETED CRISPR/CAS13 DELIVERY AND METHODS OF USE THEREOF
CN113197903B (zh) * 2021-05-08 2022-01-07 江南大学 聚普瑞锌在制备用于治疗去势抵抗性前列腺癌药物中的应用
WO2022250466A1 (ko) * 2021-05-27 2022-12-01 사회복지법인 삼성생명공익재단 전립선암의 엔잘루타미드 저항성 억제용 약학 조성물 및 엔잘루타미드 저항성을 가지는 전립선암 치료용 약학 조성물
CN113717971B (zh) * 2021-08-10 2025-03-28 南通大学 PGK1靶向siRNA干扰库及其应用
CN114324870A (zh) * 2021-12-22 2022-04-12 中国人民解放军空军军医大学 靶向髓系细胞乳酸转运信号的肺癌生物标志物和检测试剂盒
CN114246829B (zh) * 2021-12-31 2023-03-24 北京大学 一种反义核酸药物的包载方法、由该方法制备得到的药物制剂及其在肝癌治疗中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19832763A1 (de) 1997-07-21 1999-03-18 Schuster Christoph Kraftfahrzeug mit einem verschließbaren Fahrerraum
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US20030059781A1 (en) * 2000-03-21 2003-03-27 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
US6637473B2 (en) 2000-10-30 2003-10-28 Robodesign International, Inc. Automated storage and retrieval device and method
NZ538841A (en) 2002-10-02 2006-10-27 Univ British Columbia Compositions for reducing hsp27 for the treatment of prostate and other cancers
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
GB2407837B (en) 2003-11-04 2007-07-11 Corus Uk Ltd Traffic control barriers
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
US20100209914A1 (en) * 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
WO2017091885A1 (en) 2015-11-30 2017-06-08 The University Of British Columbia Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GERLINGER, M. et al., "Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target''.", Journal of Pathology, (2012-06), vol. 227, no. 2, ISSN 1096-9896, pages 146 - 156 *
HIROTO IZUMI ET AL: "Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells", CANCER SCIENCE, vol. 102, no. 5, 1 May 2011 (2011-05-01), JP, pages 1007 - 1013. *
NELMA PERTEGA-GOMES ET AL: "Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 11, no. 1, 2011, pages 312. *

Also Published As

Publication number Publication date
ES2893294T3 (es) 2022-02-08
MX2018006527A (es) 2018-11-29
AU2016363683A1 (en) 2018-07-12
EP3384028A4 (en) 2019-05-01
WO2017091885A8 (en) 2018-06-07
US11466273B2 (en) 2022-10-11
CN108603194A (zh) 2018-09-28
EP3384028A1 (en) 2018-10-10
EP3384028B1 (en) 2021-06-30
US20190010492A1 (en) 2019-01-10
US10889814B2 (en) 2021-01-12
WO2017091885A1 (en) 2017-06-08
CA3006827A1 (en) 2017-06-08
JP2019500334A (ja) 2019-01-10
US20210395733A1 (en) 2021-12-23
JP7039470B2 (ja) 2022-03-22
BR112018011045A2 (pt) 2018-11-21

Similar Documents

Publication Publication Date Title
US11466273B2 (en) Monocarboxylate transporter 4 (MCT4) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer
US10202601B2 (en) C/EBPα short activating RNA compositions and methods of use
EP3240796B1 (en) Rna interference compositions and methods for malignant tumors
US20140242192A1 (en) Clusterin Antisense Therapy for Treatment of Cancer
CN1703229B (zh) 治疗前列腺和其他癌的组合物和其制备药物的用途
WO2019239144A1 (en) Combination therapies comprising c/ebp alpha sarna
WO2018129622A1 (en) Dual targeting antisense oligonucleotides for use as apoptotic inhibitors for the treatment of cancer
US9284557B2 (en) Double-stranded nucleic acid molecule, cancer cell proliferation inhibitor and pharmaceutical agent suitable for prevention or treatment of cancer
CN113908280A (zh) Trim11抑制剂和二甲双胍的组合物在治疗肝细胞癌中的应用
CN120041444A (zh) Brix1抑制剂及其在抗肿瘤中的用途
EP4382134A1 (en) Pharmaceutical composition for preventing or treating triple-negative breast cancer, comprising oligonucleotide as active ingredient
KR102574252B1 (ko) 펩티드 핵산 복합체를 유효성분으로 함유하는 췌장암 예방 또는 치료용 조성물
WO2022127788A1 (zh) 乐伐替尼和Aurora-A激酶抑制剂在制备抑制癌症的药物中的应用
US20250205271A1 (en) Micrornas for inhibiting the expression of trf2 in tumors
BR112018011045B1 (pt) Oligonucleotídeo anti-sentido (aso), uso do mesmo na fabricação de um medicamento para o tratamento de câncer e composição farmacêutica
KR102212699B1 (ko) 유방암 예방 또는 치료용 조성물
JP5976922B2 (ja) 二本鎖核酸分子、ｄｎａ、ベクター、癌細胞増殖抑制剤、及び医薬
WO2006035515A1 (ja) 膀胱表在性癌の治療又は予防用医薬組成物､及びその利用
CN108348539A (zh) 用于治疗肿瘤的方法
HK40070347A (en) C/ebp alpha short activating rna compositions and methods of use
CN120549959A (zh) 一种靶向RAC1B的siRNA在制备治疗肺癌的药物中的应用
HK40018320A (en) C/ebp alpha short activating rna compositions and methods of use
HK40018320B (en) C/ebp alpha short activating rna compositions and methods of use

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ WANG, YUZHUO AND CHOI, STEPHEN YIU CHUEN

FGA Letters patent sealed or granted (standard patent)